Literature DB >> 28417449

Citicoline: pharmacological and clinical review, 2016 update.

J J Secades1.   

Abstract

This review is based on the previous one published in 2010 -Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol 2011; 52 (Suppl 2): S1-62-, incorporating 183 new references, having all the information available to facilitate the access to the information in one document. This review is focused on the main indications of the drug, as acute stroke and its sequelae, including the cognitive impairment, and traumatic brain injury and its sequelae. There are retrieved the most important experimental and clinical data in both indications.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28417449

Source DB:  PubMed          Journal:  Rev Neurol        ISSN： 0210-0010            Impact factor:   0.870


  11 in total

1.  Effects of citicoline administration on synaptic proteins in rapid eye movement sleep-deprived rats.

Authors:  Aysen Cakir; Busra Ocalan; Cansu Cansu; Guldal Gulec Suyen; Mehmet Cansev; Nevzat Kahveci
Journal:  Iran J Basic Med Sci       Date:  2022-05       Impact factor: 2.532

Review 2.  Role of Citicoline in the Management of Traumatic Brain Injury.

Authors:  Julio J Secades
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-26

Review 3.  Neuroprotection in Glaucoma: Old and New Promising Treatments.

Authors:  Dario Rusciano; Salvatore Pezzino; Maria Giulia Mutolo; Rossella Giannotti; Aloisa Librando; Nicola Pescosolido
Journal:  Adv Pharmacol Sci       Date:  2017-10-17

4.  Human vitreous concentrations of citicoline following topical application of citicoline 2% ophthalmic solution.

Authors:  Carmela Carnevale; Gianluca Manni; Gloria Roberti; Alessandra Micera; Luca Bruno; Andrea Cacciamani; Romeo Altafini; Luciano Quaranta; Luca Agnifili; Lucia Tanga; Ivano Riva; Francesco Oddone
Journal:  PLoS One       Date:  2019-11-14       Impact factor: 3.240

5.  Serum Levels of the Biomarkers Associated with Astrocytosis, Neurodegeneration, and Demyelination: Neurological Benefits of Citicoline Treatment of Patients with Ischemic Stroke and Atrial Fibrillation.

Authors:  O V Kuryata; Yu S Kushnir; V S Nedzvetsky; V V Korsa; A A Tykhomyrov
Journal:  Neurophysiology       Date:  2021-11-30       Impact factor: 0.587

Review 6.  Cytidine 5'-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma.

Authors:  Stefano Gandolfi; Giorgio Marchini; Aldo Caporossi; Gianluca Scuderi; Livia Tomasso; Andrea Brunoro
Journal:  Nutrients       Date:  2020-03-18       Impact factor: 5.717

7.  Application of Citicoline in Neurological Disorders: A Systematic Review.

Authors:  Patryk Jasielski; Faustyna Piędel; Mikołaj Piwek; Agata Rocka; Véronique Petit; Konrad Rejdak
Journal:  Nutrients       Date:  2020-10-12       Impact factor: 5.717

Review 8.  Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review.

Authors:  Francesco Oddone; Luca Rossetti; Mariacristina Parravano; Diego Sbardella; Massimo Coletta; Lucia Ziccardi; Gloria Roberti; Carmela Carnevale; Dario Romano; Gianluca Manni; Vincenzo Parisi
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-20

Review 9.  Citicoline and COVID-19-Related Cognitive and Other Neurologic Complications.

Authors:  Yuda Turana; Michael Nathaniel; Robert Shen; Soegianto Ali; Rajender R Aparasu
Journal:  Brain Sci       Date:  2021-12-31

10.  Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial.

Authors:  Luca Rossetti; Michele Iester; Laura Tranchina; Laura Ottobelli; Giulia Coco; Elisabetta Calcatelli; Chiara Ancona; Paola Cirafici; Gianluca Manni
Journal:  J Glaucoma       Date:  2020-07       Impact factor: 2.290
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.